Commerce Bank Purchases New Holdings in IQVIA Holdings Inc. $IQV

Commerce Bank acquired a new position in IQVIA Holdings Inc. (NYSE:IQV) in the second quarter, according to the company in its most recent filing with the SEC. The firm acquired 38,983 shares of the medical research company’s stock, valued at approximately $7,532,000.

Other institutional investors and hedge funds have also modified their holdings of the company. Brighton Jones LLC lifted its holdings in shares of IQVIA by 244.4% during the 4th quarter. Brighton Jones LLC now owns 3,575 shares of the medical research company’s stock worth $703,000 after acquiring an additional 2,537 shares during the period. Empowered Funds LLC boosted its position in shares of IQVIA by 102.1% during the 1st quarter. Empowered Funds LLC now owns 9,728 shares of the medical research company’s stock valued at $1,715,000 after acquiring an additional 4,915 shares in the last quarter. Sivia Capital Partners LLC bought a new stake in IQVIA in the second quarter valued at about $514,000. First Trust Advisors LP raised its position in IQVIA by 14.8% in the second quarter. First Trust Advisors LP now owns 92,015 shares of the medical research company’s stock worth $14,501,000 after purchasing an additional 11,845 shares in the last quarter. Finally, NewEdge Advisors LLC lifted its stake in IQVIA by 5.4% during the second quarter. NewEdge Advisors LLC now owns 22,731 shares of the medical research company’s stock worth $3,582,000 after purchasing an additional 1,155 shares during the period. 89.62% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

A number of research firms have weighed in on IQV. Royal Bank Of Canada lifted their price objective on IQVIA from $221.00 to $247.00 and gave the company an “outperform” rating in a report on Wednesday, July 29th. BMO Capital Markets raised their target price on IQVIA from $210.00 to $270.00 and gave the stock an “outperform” rating in a research report on Wednesday, July 29th. Weiss Ratings raised IQVIA from a “hold (c-)” rating to a “hold (c)” rating in a research note on Wednesday, July 15th. Barclays reiterated an “overweight” rating on shares of IQVIA in a research report on Tuesday, July 28th. Finally, JPMorgan Chase & Co. increased their price objective on IQVIA from $225.00 to $285.00 and gave the stock an “overweight” rating in a research note on Wednesday, July 29th. One research analyst has rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating and three have assigned a Hold rating to the company. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $241.88.

Insider Activity at IQVIA

In other IQVIA news, insider Bhavik Patel sold 1,855 shares of the business’s stock in a transaction dated Friday, July 31st. The shares were sold at an average price of $235.27, for a total value of $436,425.85. Following the completion of the transaction, the insider directly owned 1,348 shares of the company’s stock, valued at approximately $317,143.96. The trade was a 57.91% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, insider W Richard Staub sold 5,500 shares of the company’s stock in a transaction that occurred on Monday, August 3rd. The stock was sold at an average price of $232.68, for a total transaction of $1,279,740.00. Following the transaction, the insider owned 13,312 shares in the company, valued at $3,097,436.16. The trade was a 29.24% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last 90 days, insiders have sold 12,913 shares of company stock worth $3,098,793. 1.70% of the stock is owned by insiders.

IQVIA Price Performance

IQVIA stock opened at $260.17 on Monday. The business’s fifty day moving average is $213.32 and its two-hundred day moving average is $187.21. The company has a debt-to-equity ratio of 2.18, a quick ratio of 0.71 and a current ratio of 0.71. The firm has a market cap of $42.82 billion, a P/E ratio of 32.28, a P/E/G ratio of 2.21 and a beta of 1.18. IQVIA Holdings Inc. has a 52 week low of $154.50 and a 52 week high of $260.40.

IQVIA (NYSE:IQV) last announced its earnings results on Tuesday, July 28th. The medical research company reported $3.15 earnings per share for the quarter, beating analysts’ consensus estimates of $3.03 by $0.12. The company had revenue of $4.37 billion during the quarter, compared to analyst estimates of $4.30 billion. IQVIA had a return on equity of 30.25% and a net margin of 8.10%.The firm’s quarterly revenue was up 8.7% compared to the same quarter last year. During the same period last year, the company posted $2.81 earnings per share. IQVIA has set its FY 2026 guidance at 12.800-13.000 EPS. Equities research analysts forecast that IQVIA Holdings Inc. will post 11.57 earnings per share for the current fiscal year.

IQVIA declared that its Board of Directors has approved a share buyback plan on Thursday, May 7th that permits the company to repurchase $2.00 billion in outstanding shares. This repurchase authorization permits the medical research company to purchase up to 6.8% of its stock through open market purchases. Stock repurchase plans are generally a sign that the company’s board believes its shares are undervalued.

IQVIA Profile

IQVIA (NYSE: IQV) is a global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. The company combines clinical research capabilities with large-scale health data and analytics to support drug development, regulatory reporting, commercial strategy and real?world evidence generation. IQVIA traces its current form to the combination of Quintiles and IMS Health announced in 2016 and subsequently rebranded as IQVIA, bringing together long-established clinical research operations and extensive healthcare information assets.

IQVIA’s principal activities include outsourced clinical development services (acting as a contract research organization for phases I–IV), real?world evidence and observational research, regulatory and safety services, and a suite of technology platforms that enable data integration, analytics and operational management.